Diabetes type 2, microalbuminuria
Conditions
Interventions
During 3 consecutive months, the intervention group receives 200 mg of MOF once daily in the form of a commercially available Food for Special Medical Purposes (Endoclair), whereas the control group r
Sponsors
Erasmus Medical Center, Department of Internal Medicine
Eligibility
Inclusion criteria
Inclusion criteria: • T2D • Age 40-85 years • Microalbuminuria in the previous 6 months (as microalbuminuria can change during time, results shouldn’t be older than 6 months), defined as: - 30-300 mg albumin in a 24-hour urine sample - or 3.5-35 mg albumin/mmol creatinine in females and 2.5-25 mg albumin/mmol creatinine in males in a urine portion. This definition is derived from the Dutch national guidelines.
Exclusion criteria
Exclusion criteria: • Other types of diabetes mellitus as derived from the medical records • Prior (less than 4 weeks before participating) or current use of any specific dietary supplementary products providing daily amounts of MOF of 25 mg/day or higher • Anticoagulation medication • Major health conditions: organ transplantation, untreated cancer, current chemotherapy or radiotherapy, acute or chronic organ failure • Microalbuminuria due to other conditions than T2D • Pregnancy or lactation during the trial
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Renal endothelial function will be measured before, during and after the intervention using albumin excretion rate in 24h urine (AER) | — |
Secondary
| Measure | Time frame |
|---|---|
| Established plasma biomarkers for renal endothelial function, namely asymmetric dimethylarginine (ADMA), vascular cell adhesion molecule 1 (VCAM-1), interleukin 6 (IL-6), von Willebrand Factor (vWF) and intercellular cell adhesion molecule 1 (ICAM-1). | — |
Contacts
Public ContactKirsten Berk
Erasmus Medical Center
Outcome results
None listed